Please login to the form below

Not currently logged in
Email:
Password:

NKT-214

This page shows the latest NKT-214 news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

BMS presses go on Nektar combo pivotal trials, despite data debate

Specifically, Opdivo and NKTR-214 achieved an overall response rate (ORR) of 85% in stage 1 - i.e. ... In fact, they have data which suggests NKTR-214 can actually make PD-L1-negative tumours start expressing the biomarker.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics